Information Products on Pharmaceuticals - Renouf Publishing Co. Ltd.

oms-catalogue 15/07/03 11:34 Page 25
LEGISLATION AND REGULATION
International Travel
and Health 2003
Situation as on 1 January 2003
Effective Drug Regulation
A Multicountry Study
Guidelines for the
Regulatory Assessment
of Medicinal <strong>Products</strong>
for Use in Self-medication
This edition of International
travel and health was completely
redesigned in 2002 to reflect better
knowledge about the risks to
which travellers are exposed and
the precautions needed to protect
their health.
The book offers guidance on the
full range of health risks likely to
be encountered at specific destinations
and associated with different
types of travel - from business,
humanitarian and leisure travel to
backpacking and adventure tours.
<strong>Information</strong> is intended to help the
medical profession be fully alert to
potential risks and provide appropriate
advice, whether concerning
recommended vaccinations, protection
against insects and other disease
vectors, or safety in different
environmental settings. <strong>Information</strong>
on infectious diseases of potential
risk for travellers has also been
greatly expanded. Additional chapters
describe vaccine-preventable
diseases, vaccines for routine and
selective use, and selection criteria,
and offer detailed guidance
on malaria, the most important
infectious disease threat for
travellers.
Drugs play a crucial role in saving
lives, restoring health, and preventing
diseases and epidemics. But
they need to be safe, efficacious,
of good quality, and used rationally.
This means that their production,
import/export, storage, supply and
distribution should be subject to
government control through prescribed
norms and standards and
an effective regulatory system.
Substandard and counterfeit drugs
proliferate primarily in an environment
where drug regulation has
proved ineffective.
This publication presents a
synthesis of studies on drug
regulation carried out in 10
countries: Australia, Cuba, Cyprus,
Estonia, Malaysia, the Netherlands,
Tunisia, Uganda, Venezuela, and
Zimbabwe in 1998-1999. It gives
an overview of the development of
drug regulation in these countries
as well as the resources available
and the strategies applied in drug
regulation implementation at the
time the studies were conducted.
An analysis of the strengths and
weaknesses in drug regulation in
these countries is also provided.
Presents guidelines for determining
when medicinal products, sold on
prescription only, can be reclassified
for non-prescription, or over-thecounter,
sale. Noting that self-medication
plays an important role in
the health care system, the booklet
sets out criteria and methods
intended to help drug regulatory
authorities decide when a product
is suitably safe and effective for
self-medication.
25
2002, vii + 85 pages [E, F]
ISBN 92 4 158028 3
Swiss francs 25.–/US $22.50
In developing countries: Sw.fr. 17.50
Order no. 1180003
by S. Ratanawijitrasin and
E. Wondemagegnehu
2002, ix + 189 pages [E]
ISBN 92 4 156206 4
Swiss francs 20.–/US $18.00
In developing countries: Sw.fr. 14.–
Order no. 1150503
2000, 31 pages [E]
WHO/EDM/QSM/00.1
Swiss francs 10.–/US $9.00
In developing countries: Sw.fr. 7.–
Order no. 1930175